Metabolomics analysis reveals the association between lipid abnormalities and oxidative stress, inflammation, fibrosis, and Nrf2 dysfunction in aristolochic acid-induced nephropathy

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Zhao, Ying Yong ^a,b   Wang, Hui Ling ^f   Cheng, Xian Long ^d   Wei, Feng ^d   Bai, Xu ^e   Lin, Rui Chao ^c   Vaziri, Nosratola D ^b  

^a NORTHWEST UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^d NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

^e Waters Technologies Shanghai Ltd   (China)

^f Jimin Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARISTOLOCHIC ACID; ARISTOLOCHIC ACID I; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID; NFE2L2 PROTEIN, RAT; TRANSCRIPTION FACTOR NRF2; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL;

ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; INFLAMMATION; INTERSTITIAL NEPHRITIS; KIDNEY; MALE; METABOLISM; METABOLOMICS; OXIDATIVE STRESS; PHYSIOLOGY; PROCEDURES; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ARISTOLOCHIC ACIDS; DISEASE MODELS, ANIMAL; FIBROSIS; INFLAMMATION; KIDNEY; LIPIDS; MALE; METABOLOMICS; NEPHRITIS, INTERSTITIAL; NF-E2-RELATED FACTOR 2; NF-KAPPA B; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; TRANSFORMING GROWTH FACTOR BETA; TRIGLYCERIDES;

EID: 84938779862     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12936     Document Type: Article

References (30)

1. Debelle, F. D., Vanherweghem, J. L. &Nortier, J. L. Aristolochic acid nephropathy: A worldwide problem. Kidney Int. 74, 158-169 (2008).
2. Zhou, L. et al. Mechanism of chronic aristolochic acid nephropathy: role of Smad3. Am. J. Physiol. Renal Physiol. 298, F1006-F1017 (2010).
3. Debelle, F. D. et al. Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt-depleted rats. J. Am. Soc. Nephrol. 13, 431-436 (2002).
4. Cosyns, J. P. et al. Chronic aristolochic acid toxicity in rabbits: a model of Chinese herbs nephropathy? Kidney Int. 59, 2164-2173 (2001).
5. Zhao, Y. Y. &Lin, R. C. Metabolomics in Nephrotoxicity. Adv. Clin. Chem. 65, 69-89 (2014).
6. Vanherweghem L. J. Misuse of herbal remedies: the case of an outbreak of terminal renal failure in Belgium (Chinese herbs nephropathy). J. Altern. Complement. Med. 4: 9-13 (1998).
7. Zhao, Y. Y. et al. Intrarenal metabolomic investigation of chronic kidney disease and its TGF-β 1 mechanism in induced-adenine rats using UPLC Q-TOF/HSMS/MSE. J. Proteome Res. 12, 692-703 (2013).
8. Zhao, Y. Y. et al. Application of faecal metabonomics on an experimental model of tubulointerstitial fibrosis by ultra performance liquid chromatography/high-sensitivity mass spectrometry with MSE data collection technique. Biomarkers 17, 721-729 (2012).
9. Aminzadeh, M. A. et al. Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulo-interstitial nephropathy. Nephrol. Dial. Transplant. 28, 2038-2045 (2013).
10. Aminzadeh, M. A. et al. Role of impaired Nrf2 activity in chronic kidney disease-induced endothelial dysfunction and its restoration with the Synthetic Triterpenoid RTA dh404. Redox Biol. 1, 527-531 (2013).
11. Ruiz, S. et al. Targeting Nrf2 activation to ameliorate oxidative stress and inflammation in Chronic Kidney Disease. Kidney Int. 83, 1029-1041 (2013).
12. Lin, S. et al. Liquid chromatography/mass spectrometry for investigating the biochemical effects induced by aristolochic acid in rats: the plasma metabolome. Rapid Commun. Mass Spectrom. 24, 1312-1318 (2010).
13. Ni, Y. et al. Metabolic profiling using combined GC-MS and LC-MS provides a systems understanding of aristolochic acidinduced nephrotoxicity in rat. FEBS Lett. 581, 707-711 (2007).
14. Morash, S. C., Cook H. W. &Spence, M. W. Lysophosphatidylcholine as an intermediate in phosphatidylcholine metabolism and glycerophosphocholine synthesis in cultured cells: an evaluation of the roles of 1-acyl-and 2-acyl-lysophosphatidylcholine. Biochim. Biophys. Acta-lip. Lip. metab. 1004(2), 221-229 (1989).
15. Dunlop, M. E., Muggli, E. &Clark, S. Differential disposition of lysophosphatidylcholine in diabetes compared with raised glucose: Implications for prostaglandin production in the diabetic kidney glomerulus in vivo. Biochim. Biophys. Acta. 1345, 306-316 (1997).
16. Yamashita, A. et al. Subcellular localization and lysophospholipase/transacylation activities of human group IVC phospholipase A2. Biochim. Biophys. Acta-Mol. Cell Biol. Lip. 1791, 1011-1022 (2009).
17. Vance, D. E. Physiological roles of phosphatidylethanolamine N-methyltransferase. Bioch. Biophys. Acta-Mol. Cell Biol. Lipid. 1831, 626-632 (2013).
18. Iwase, M. et al. Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: Relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment. Atherosclerosis 196, 931-936 (2008).
19. Zhao, Y. Y. et al. Renal metabolic profiling of early renal injury and renoprotective effects of Poria cocos epidermis using UPLC Q-TOF/HSMS/MSE. J. Pharm. Biomed. Anal. 81-82, 202-209 (2013).
20. Zhao, Y. Y. et al. A pharmaco-metabonomic study on chronic kidney disease and therapeutic effect of ergone by UPLC-QTOF/ HDMS. Plos One 9, e115467 (2014).
21. Kim, H. J. &Vaziri, N. D. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am. J. Physiol. Renal Physiol. 298, F662-F671 (2010).
22. Prabu, S. M. &Muthumani, M. Silibinin ameliorates arsenic induced nephrotoxicity by abrogation of oxidative stress, inflammation and apoptosis in rats. Mol. Biol. Rep. 39, 11201-11216 (2012).
23. Gui, S. et al. Renal injury and Nrf2 modulation in mouse kidney following chronic exposure to TiOnanoparticles. J. Agric. Food Chem. 61, 8959-8968 (2013).
24. Kang, H. M. et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat. Med. 21, 37-46 (2015).
25. Indiveri, C. et al. The mitochondrial carnitine/acylcarnitine carrier: function, structure and physiopathology. Mol. Aspects. Med. 32, 223-233 (2011).
26. Vaziri, N. D. et al. Downregulation of hepatic acyl-CoA: diglycerol acyltransferase in chronic renal failure. Am. J. Physiol. Renal Physiol. 287, F90-F94 (2004).
27. Srivastava, S. P. et al. Lipid mediators in diabetic nephropathy. Fibrogenesis Tissue Repair. 7, 12 (2014).
28. Zhao, Y. Y. et al. Ultra performance liquid chromatography-based metabonomic study of therapeutic effect of the surface layer of Poria cocos on adenine-induced chronic kidney disease provides new insight into anti-fibrosis mechanism. Plos One 8, e59617 (2013).
29. Kim, H. J. &Vaziri, N. D. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am. J. Physiol. Renal Physiol. 298, F662-F671 (2010).
30. Zhao, Y. Y. et al. Effect of ergosta-4,6,8(14),22-tetraen-3-one (ergone) on adenine-induced chronic renal failure rat: a serum metabonomic study based on ultra performance liquid chromatography/high-sensitivity mass spectrometry coupled with MassLynx i-FIT algorithm. Clin. Chim. Acta. 413, 1438-1445 (2012).